Identifying patients at risk for myasthenic crisis with hemogram and inflammation-related laboratory parameters – a pilot study

myasthenia gravis 03 medical and health sciences hemogram 0302 clinical medicine Neurology myasthenic crisis inflammation laboratory parameters Neurology. Diseases of the nervous system RC346-429 myasthenia
DOI: 10.1101/2023.09.19.23295421 Publication Date: 2023-09-20T20:15:23Z
ABSTRACT
ABSTRACTBackgroundMyasthenia gravis (MG) is a rare autoimmune disease characterized by fatigable weakness of the voluntary muscles and can exacerbate to life-threatening myasthenic crisis (MC), requiring intensive care treatment. Routine laboratory parameters are a cost-effective and widely available method for estimating clinical outcomes of several diseases, but so far such parameters have not been established to detect disease progression in MG.MethodsWe conducted a retrospective analysis of selected laboratory parameters related to inflammation and hemogram for MG patients with MC matched to MG patients without MC. To identify potential risk factors for MC, we applied time-varying Cox regression for time to MC, and as a sensitivity analysis generalized estimating equations logistic regression for the occurrence of MC at the next patient visit.Results15 of the 58 examined MG patients suffered at least one MC. There was no notable difference in the occurrence of MC by antibody status or sex. Both regression models showed that higher counts of basophils (per 0.01 units increase: HRlJ=lJ1.32, 95% CIlJ=1.02-1.70), neutrophils (per 1 unit increase: HRlJ=lJ1.40, 95% CIlJ=lJ1.14-1.72), and potentially leukocytes (per 1 unit increase: HR = 1.15, 95% CI = 0.99-1.34), and platelets (per 100 units increase: HR = 1.54, 95% CI = 0.99-2.38) may indicate increased risk for a myasthenic crisis.ConclusionThis pilot study provides proof of concept that increased counts of basophils, neutrophils, leukocytes, and platelets may be associated with a higher risk for developing MC in patients with MG.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (41)
CITATIONS (1)